ArgusEye closes €2.8 million funding to accelerate bioprocessing

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the close of its funding, raising €2.8 million EUR (~£2.4 million GBP) bringing the total raised by the Company to €3.45 million EUR (~£3 million GPB). The funding was led by Voima Ventures, a Nordic early-stage investor that specializes in supporting science-based solutions, and co-led by existing investor Eir Ventures, a Scandinavian life science venture capital fund, following its investment into ArgusEye’s seed funding. The investment will support the continued development of the Company’s sensor system platform, Auga™, designed to accelerate biotherapeutic development and manufacture.

Established in 2017 by Erik Martinsson and Daniel Aili, ArgusEye develops novel sensors to enable real-time monitoring and analysis of biological systems and processes. Leveraging 15 years of research, Erik and Daniel initiated their partnership at a laboratory in Linköping, Sweden, developing ArgusEye’s localized surface plasmon resonance (LSPR) technology, which uses gold nanoparticles for precise and targeted protein measurements, and formed the basis of ArgusEye’s technology. Following its partnership with Bayer in 2021, ArgusEye has continued to validate its technology and expand its customer base.

In traditional biopharmaceutical manufacturing, quality control involves labor intensive remote testing, leading to significant delays in defect detection. Introduced in March 2024, the AugaOne™ is the first product in the Company’s sensor system platform, Auga, and is specifically adapted for downstream processing to increase process efficiency and intensify process development to accelerate detection and quantification of mAbs. The investment will enable ArgusEye to expand the Auga platform to support upstream bioprocessing and formulation of a wide range of target molecules, transforming biotherapeutic development and production.

Jenny Engerfelt, Investment Director at Voima Ventures, said:“ArgusEye's technology holds the promise of driving down healthcare costs by improving efficiency in biopharmaceutical manufacturing processes, leading to better health outcomes for more people.”

As one of the main shareholders in the company, we are extremely proud and excited to further support ArgusEye’s journey of bringing revolutionary sensor technologies for next generation bioprocessing to life, enabling automated development and production of medicines to make them accessible to a larger part of the population with a reduced ecological footprint."

Lene Gerlach, Partner at Eir Ventures

Erik Martinsson, CEO at ArgusEye, said: "As ArgusEye embarks on its scale-up phase, our focus is twofold: expanding our market footprint geographically and diversifying our product offerings to encompass the entire pharmaceutical process chain, from upstream cell growth to downstream purification and late-stage formulation as well as GMP production. This strategic approach aligns with our commitment to deliver cutting-edge solutions that address the evolving needs of the biopharmaceutical industry and our vision to enable a more sustainable and democratic reach of biomedicines, transforming biopharma manufacturing through real-time inline quality control."

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ArgusEye AB. (2024, May 13). ArgusEye closes €2.8 million funding to accelerate bioprocessing. News-Medical. Retrieved on June 16, 2024 from https://www.news-medical.net/news/20240513/ArgusEye-closes-e282ac28-million-funding-to-accelerate-bioprocessing.aspx.

  • MLA

    ArgusEye AB. "ArgusEye closes €2.8 million funding to accelerate bioprocessing". News-Medical. 16 June 2024. <https://www.news-medical.net/news/20240513/ArgusEye-closes-e282ac28-million-funding-to-accelerate-bioprocessing.aspx>.

  • Chicago

    ArgusEye AB. "ArgusEye closes €2.8 million funding to accelerate bioprocessing". News-Medical. https://www.news-medical.net/news/20240513/ArgusEye-closes-e282ac28-million-funding-to-accelerate-bioprocessing.aspx. (accessed June 16, 2024).

  • Harvard

    ArgusEye AB. 2024. ArgusEye closes €2.8 million funding to accelerate bioprocessing. News-Medical, viewed 16 June 2024, https://www.news-medical.net/news/20240513/ArgusEye-closes-e282ac28-million-funding-to-accelerate-bioprocessing.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.